No drug targets autism’s core symptoms, but medications from antipsychotics to leucovorin can address irritability, sleep, attention, and other co-occurring challenges.

DSM-5 loosened the criteria for adult ADHD, but did it get too lose? We look at what recent prosecutions of telehealth companies mean for those trying to diagnose this disorder on the front-lines.

Women clear some psychiatric medications more slowly, lose bone density at higher rates, and face greater medical consequences from alcohol and smoking than men. This final episode in a four-part series covers side effects, drug metabolism, drugs of abuse, urine incontinence, and what we do — and don't — know about prescribing for transgender patients.

Estrogen shapes nearly every neurotransmitter system in the brain, and when it starts to fall, psychiatric disorders often follow. This episode walks through what psychiatrists need to know about the perimenopause: which conditions worsen, which treatments help, and when to call the OB-GYN about hormone replacement therapy.

Premenstrual hormones can destabilize mood, worsen ADHD, trigger psychosis, and drive binge eating. This episode walks through the tools to manage hormonal fluctuations in female patients, from SSRIs to overlooked supplements to the lamotrigine-contraceptive drug interaction.

Women and men respond to psychiatric medications differently. In this first of a four-part series, Chris Aiken and Kellie Newsome walk through why valproate is risky for women, and when it’s worth using; why the FDA cut the zolpidem dose in half for female patients, and why SSRIs outperform tricyclics in women with depression. Plus: a sneak preview of DSM-6.

Two malpractice cases — one worth $2 million — are reshaping the standards of gender-affirming care. This episode traces what went wrong, what held up in court, and what every clinician needs to know when referring patients for gender affirming procedures.

If a patient is tapering off SSRIs completely — rather than switching to another antidepressant — a hyperbolic taper minimizes the risk of withdrawal.

When Dr. Chris Aiken opened a psychotherapy practice in Western North Carolina, treatment-resistant depression wasn’t a specialty he planned for — it was what walked through the door. Most patients arrived having already failed one or more SSRIs prescribed in primary care. The standard next steps — raising the dose, switching classes, adding bupropion, buspirone, or a stimulant — often weren’t enough.